NCT06253702View on ClinicalTrials.gov

Brain Blood Flow Responses to Stress: Sex Differences

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Cerebrovascular Disorders
Interventions
DRUG

Indomethacin

to inhibit cyclooxygenase (COX)

DRUG

Placebo

Placebo

DRUG

Orilissa

to suppress hormones 200mg dose 2x per day (all participants)

DRUG

Testosterone gel

50 mg each morning for add back phase (male participants)

DRUG

Anastrozole

1mg/day in men to prevent conversion of testosterone to estradiol

DRUG

Estradiol

Women will receive oral estradiol 2mg/daily

Trial Locations (1)

53705

University of Wisconsin, Madison

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT06253702 - Brain Blood Flow Responses to Stress: Sex Differences | Biotech Hunter | Biotech Hunter